Cargando…

Approaching treatment for immunological rejection of living-donor liver transplantation in rats

BACKGROUND: The anti-immunological rejection therapy for small-for-size syndrome (SFSS) after live donor liver transplantation (LDLT) play a central role in keeping graft survival. The hepatocyte number and grafts function has undergone real-time changes with the proliferation and apoptosis of the g...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Yanhu, Han, Zhijian, Feng, Zedong, Wang, Bofang, Cheng, Huijuan, Yang, Luxi, Li, Yangbing, Gu, Baohong, Li, Xuemei, Li, Yahao, Li, Yumin, Wang, Chen, Chen, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6956502/
https://www.ncbi.nlm.nih.gov/pubmed/31931737
http://dx.doi.org/10.1186/s12876-019-1130-x
_version_ 1783487167332352000
author Feng, Yanhu
Han, Zhijian
Feng, Zedong
Wang, Bofang
Cheng, Huijuan
Yang, Luxi
Li, Yangbing
Gu, Baohong
Li, Xuemei
Li, Yahao
Li, Yumin
Wang, Chen
Chen, Hao
author_facet Feng, Yanhu
Han, Zhijian
Feng, Zedong
Wang, Bofang
Cheng, Huijuan
Yang, Luxi
Li, Yangbing
Gu, Baohong
Li, Xuemei
Li, Yahao
Li, Yumin
Wang, Chen
Chen, Hao
author_sort Feng, Yanhu
collection PubMed
description BACKGROUND: The anti-immunological rejection therapy for small-for-size syndrome (SFSS) after live donor liver transplantation (LDLT) play a central role in keeping graft survival. The hepatocyte number and grafts function has undergone real-time changes with the proliferation and apoptosis of the grafts after reperfusion. Lacking an accurate and effective treatment regiments or indicators to guide the use of immunosuppressive drugs in SFS liver transplantation has made immunotherapy after SFS liver transplantation an urgent problem to be solved. Herein, we established small-for-size (SFS) and normal size liver transplantation model in rats to explore the effective indicators in guiding immunotherapy, to find an effective way for overcoming SFSS. METHODS: Lewis rats (donors) and BN rats (recipients) were used to mimic allograft liver transplantation and treated with tacrolimus. Local graft immune response was analyzed through haematoxylin and eosin and immunohistochemistry. Flow cytometry was used to assess the overall immune status of recipient. The pharmacokinetics mechanism of immunosuppressive drugs was explored through detecting CYP3A2 expression at mRNA level and protein levels. RESULTS: The results showed the local immune reaction of SFS grafts and systemic immune responses of recipient were significantly increased compared with those in normal size grafts and their recipient at four days after liver transplantation. Regression equation was used to regulate the tacrolimus dose which not only controlled tacrolimus serum concentration effectively but alleviated liver damage and improved survival rate. CONCLUSIONS: This study showed that AST level and tacrolimus serum concentrations are effective indicators in guiding immunotherapy. Regression equation (T(D) = − 0.494T(C)-0.0035AST + 260.487) based on AST and tacrolimus serum concentration can be used as a reference for adjustment of immunotherapy after SFS liver transplantation, which is applicable in clinical practice.
format Online
Article
Text
id pubmed-6956502
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-69565022020-01-17 Approaching treatment for immunological rejection of living-donor liver transplantation in rats Feng, Yanhu Han, Zhijian Feng, Zedong Wang, Bofang Cheng, Huijuan Yang, Luxi Li, Yangbing Gu, Baohong Li, Xuemei Li, Yahao Li, Yumin Wang, Chen Chen, Hao BMC Gastroenterol Research Article BACKGROUND: The anti-immunological rejection therapy for small-for-size syndrome (SFSS) after live donor liver transplantation (LDLT) play a central role in keeping graft survival. The hepatocyte number and grafts function has undergone real-time changes with the proliferation and apoptosis of the grafts after reperfusion. Lacking an accurate and effective treatment regiments or indicators to guide the use of immunosuppressive drugs in SFS liver transplantation has made immunotherapy after SFS liver transplantation an urgent problem to be solved. Herein, we established small-for-size (SFS) and normal size liver transplantation model in rats to explore the effective indicators in guiding immunotherapy, to find an effective way for overcoming SFSS. METHODS: Lewis rats (donors) and BN rats (recipients) were used to mimic allograft liver transplantation and treated with tacrolimus. Local graft immune response was analyzed through haematoxylin and eosin and immunohistochemistry. Flow cytometry was used to assess the overall immune status of recipient. The pharmacokinetics mechanism of immunosuppressive drugs was explored through detecting CYP3A2 expression at mRNA level and protein levels. RESULTS: The results showed the local immune reaction of SFS grafts and systemic immune responses of recipient were significantly increased compared with those in normal size grafts and their recipient at four days after liver transplantation. Regression equation was used to regulate the tacrolimus dose which not only controlled tacrolimus serum concentration effectively but alleviated liver damage and improved survival rate. CONCLUSIONS: This study showed that AST level and tacrolimus serum concentrations are effective indicators in guiding immunotherapy. Regression equation (T(D) = − 0.494T(C)-0.0035AST + 260.487) based on AST and tacrolimus serum concentration can be used as a reference for adjustment of immunotherapy after SFS liver transplantation, which is applicable in clinical practice. BioMed Central 2020-01-13 /pmc/articles/PMC6956502/ /pubmed/31931737 http://dx.doi.org/10.1186/s12876-019-1130-x Text en © The Author(s). 2020 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Feng, Yanhu
Han, Zhijian
Feng, Zedong
Wang, Bofang
Cheng, Huijuan
Yang, Luxi
Li, Yangbing
Gu, Baohong
Li, Xuemei
Li, Yahao
Li, Yumin
Wang, Chen
Chen, Hao
Approaching treatment for immunological rejection of living-donor liver transplantation in rats
title Approaching treatment for immunological rejection of living-donor liver transplantation in rats
title_full Approaching treatment for immunological rejection of living-donor liver transplantation in rats
title_fullStr Approaching treatment for immunological rejection of living-donor liver transplantation in rats
title_full_unstemmed Approaching treatment for immunological rejection of living-donor liver transplantation in rats
title_short Approaching treatment for immunological rejection of living-donor liver transplantation in rats
title_sort approaching treatment for immunological rejection of living-donor liver transplantation in rats
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6956502/
https://www.ncbi.nlm.nih.gov/pubmed/31931737
http://dx.doi.org/10.1186/s12876-019-1130-x
work_keys_str_mv AT fengyanhu approachingtreatmentforimmunologicalrejectionoflivingdonorlivertransplantationinrats
AT hanzhijian approachingtreatmentforimmunologicalrejectionoflivingdonorlivertransplantationinrats
AT fengzedong approachingtreatmentforimmunologicalrejectionoflivingdonorlivertransplantationinrats
AT wangbofang approachingtreatmentforimmunologicalrejectionoflivingdonorlivertransplantationinrats
AT chenghuijuan approachingtreatmentforimmunologicalrejectionoflivingdonorlivertransplantationinrats
AT yangluxi approachingtreatmentforimmunologicalrejectionoflivingdonorlivertransplantationinrats
AT liyangbing approachingtreatmentforimmunologicalrejectionoflivingdonorlivertransplantationinrats
AT gubaohong approachingtreatmentforimmunologicalrejectionoflivingdonorlivertransplantationinrats
AT lixuemei approachingtreatmentforimmunologicalrejectionoflivingdonorlivertransplantationinrats
AT liyahao approachingtreatmentforimmunologicalrejectionoflivingdonorlivertransplantationinrats
AT liyumin approachingtreatmentforimmunologicalrejectionoflivingdonorlivertransplantationinrats
AT wangchen approachingtreatmentforimmunologicalrejectionoflivingdonorlivertransplantationinrats
AT chenhao approachingtreatmentforimmunologicalrejectionoflivingdonorlivertransplantationinrats